Physician profile
Carly E Canavan
NPI 1578171492
$3,001.10
in general payments reported to CMS, 2019-2025
32 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $754 · 2022: $921 · 2023: $551 · 2024: $460 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.25 | 2021-2025 | |
| Novo Nordisk INC | $398.64 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $321.89 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $316.09 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $143.91 | 2021 | |
| Exact Sciences Corporation | $143.05 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $114.25 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.21 | 2021-2022 | |
| Astellas Pharma US INC | $79.29 | 2021-2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $76.97 | 2022 | |
| Merck Sharp & Dohme LLC | $72.69 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $69.32 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $60.85 | 2022-2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.85 | 2022-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $50.16 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38.19 | 2022 | |
| Sanofi Pasteur INC. | $32.96 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.91 | 2025 | Caplyta |
| Kyowa Kirin, INC. | $26.35 | 2025 | |
| Gilead Sciences, INC. | $24.11 | 2025 | |
| Eisai INC. | $23.55 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.06 | 2021 | |
| Seqirus USA INC | $19.84 | 2022 | |
| Renalytix Ai, INC. | $19.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.95 | 2021 | |
| Bausch Health US, LLC | $18.81 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.16 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $18.00 | 2024 | Airsupra |
| Rgh Enterprises LLC | $16.20 | 2024 | |
| Sanofi-Aventis U.S. LLC | $14.91 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.69 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.99 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Canavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.